CDKN2A and breast carcinoma: According to Lubecka et al. [91], the combinatorial treatment of SFN with clofarabine could induce a significant decline of cancer cell growth and up-regulation of CDKN2A (a tumor suppressor gene highly hypermethylated in breast cancer cells).